Skip to main content

Taggar

andningsvägar

cancer

diabetes

forskning & utveckling

hjärta/kärl

ledning

mage/tarm

neurovetenskap

AstraZeneca 220 cancer 112 forskning & utveckling 110 hjärta/kärl 82 diabetes 59 andningsvägar 29 mage/tarm 14 neurovetenskap 11 FDA 10 onkologi 8 seroquel 7 delårsrapport 7 infektion 7 forskning 6 akut kranskärlssjudom 6 Observationsstudie 6 medimmune 6 astma 6 influensavaccin 5 forxiga 5 Tagrisso 5 vandetanib 5 ledning 5 bokslutsrapport 5 naloxegol 5 motavizumab 5 RWE 5 egfr-testning 5 olaparib 4 antibiotika 4 bristol-myers squibb 4 fostamatinib 4 tc-5214 4 lungcancer 4 karolinska institutet 4 seroquel xr 4 ledgångsreumatism 4 fluenz 4 selumetinib 3 slusg 3 CVD-REAL 3 produkt 3 astra tech 3 kroniskt obstruktiv lungsjukdom 3 osimertinib 3 styrelsen 3 subvention 3 japan 3 antibiotikaresistens 3 pathos 3 gefitinib 3 crestor® 3 egentlig depression 3 vimovo 3 anders ekblom 3 tyskland 2 samarbete 2 återfall 2 mdd 2 bydureon 2 ticagrelor 2 astrazenca 2 benralizumab 2 life science 2 individanpassad behandling 2 epanova 2 smärta 2 acalabrutinib 2 saturn 2 kina 2 Real World evidence 2 caprelsa 2 typ2diabetes 2 klopidogrel 2 entocort 2 registerstudie 2 opioider 2 ardea biosciences 2 byetta 2 seroquel xr (quetiapin fumarat) 2 slusg stipendium 2 patenttvist 2 confirm 2 seroquel xl 2 Brilique 2 almedalen 2 recentin 2 targacept 2 kvartalsrapport 2 läkemedelsförmånen 2 axanum 2 fulvestrant 2 beslut 1 2009 annual scientific meeting in philadelphia 1 egfr-muterad 1 tobias ankner 1 bioläkemedel 1 bypass 1 läkemedel 1 skelettmetastaser 1 non-executive director 1 hha 1 flumist 1 tlv 1 lesinurad 1 durvalumab 1 internationell konkurrens 1 formuleringspatent 1 exenatide 1 målstyrt läkemedel 1 kombiglyze xr 1 mikael agaton 1 ny indikation 1 stroke 1 pegasus 1 patent 1 barninfluensavaccin 1 osimertinub 1 influensanässpray 1 u.s. food and drug administration (fda) 1 zibotentan 1 berzeliussamlingen 1 generiskt esomeprazolmagnesium 1 sponsring 1 eurika 1 aks 1 pris läkemedel 1 asco 1 zactima (vandetanib) 1 styrelseordförande 1 produktion 1 DAISY 1 typ 2-diabetes 1 blodsockerkontroll 1 avancerad hormonkänslig bröstcancer 1 mrsa 1 lund 1 syntetisk kemi 1 stipendieprogram 1 r&d 1 nässprayvaccin 1 den amerikanska läkemedelsmyndigheten 1 förstoppning 1 dapagliflozin 1 apotex inc (notice of compliance 1 lesinurab 1 forsknings - och utvecklingscentra 1 årsredovisning 2011 1 immunoterapier 1 tre strategiska centra 1 komboglyze 1 moventig 1 mcrc 1 kolorektalcancer 1 ldl-c 1 inflammation 1 nytt läkemedel lungcancer 1 grymt fett 1 hjärt-och kärlsjukdom 1 pluto-studien 1 patologi 1 first studien 1 avancerad bröstcancer 1 egfr mutation 1 forskningsportfölj 1 högkostnadsskyddet 1 kastrationsresistent 1 moderna therapeutics 1 journal of clinical oncology 1 hans andersson 1 päivi tolstoy 1 ceftarolinfosamil 1 ordnat införande Almedalen 1 EGFR 1 antaros 1 fas 3-studie 1 sekundärprevention 1 citizens petition 1 hälsoekonomiska data 1 anastrozol 1 arbetsmarknadsdagar 1 motivationsstöd 1 Lynparza 1 ovarian cancer 1 bakterier 1 varumärkta generika 1 ämnesomsättningssjukdomar (emdac) 1 kol 1 vaccinet 1 roger henriksson 1 bröstcancer utmärkelse 2012 1 astrazeneca lund 1 hudinfektioner 1 forskarstipendium 1 myalept 1 azd9773 1 sumitomo 1 stipendier 1 alzheimers 1 vimovotm 1 non-small cell lung cancer 1 bevacizumab 1 Uppsala Clinical Research Center 1 konkurrenskraften 1 opioidbehandling 1 usa 1 lipodystrofi 1 citizen petitions 1 e-brilique 1 CVD-REAL Nordic 1 produktionsanläggning 1 jonas bergh 1 jan lundberg 1 denosumab 1 bioventurehub 1 noc) 1 blodförgiftning 1 läkemedelsforskning 1 kanadensiska hälsovårdsministeriet 1 subventioner 1 cancerregister 1 max planck institute 1 corporate 1 hälsoekonomi 1 kranskärlsjukdom 1 h1n1 1 mobiltelefonapplikation 1 per hamid ghatan 1 pfizer 1 lungcancersymtom 1 caz-avi 1 tonårshjärnan 1 metabola sjukdomar 1 biohub 1 antidepressiva läkemedel 1 farxiga 1 läkemedelsforskningen 1 cediranib 1 generiska läkemedel 1 behandling lungcancer 1 toprol-xl 1 skatteärende 1 invasiv behandling 1 cardiologföreningen 1 kyntheum 1 non-small-cell lungcancer 1 glp-1 agonister 1 blodsockerfall 1 savor 1 gonorré 1 SUPPORT-studien 1 certriad 1 monoterapi 1 Imfinzi 1 hormonresistent 1 scilifelab 1 livskvalitet lungcancer 1 david brennan 1 prismodell 1 atac 1 karolinska universitetssjukhuset 1 astma/kol 1 kvalitetsregister 1 elisabeth björk 1 arimidex 1 patientstöd 1 artros 1 influensa 1 zinforo 1 translationell 1 leif johansson 1 quetiapin fumarat 1 per alfredsson 1 faslodex (fulvestrant) 1 mobil-app 1 patient websida 1 sepsis 1 pegasus-timi 1 delårsrapport januari-september 2011 1 mjukdelsinfektioner 1 hjärinfarkt 1 hjärtinfarkt 1 klinisk forsk 1 egfr positiv 1 nytt läkemedel mot lungcancer 1 advaxis 1 medicon village 1 QTERN 1 exacerbationer 1 årsredovisning 2010 1 eu 1 pozen 1 nda 1 forskare 1 SvFP 1 merck-avtal 1 ämnesomsättningssjukdomar 1 esc 1 the medicines company 1 brodalumab 1 nikotinkanalsblockerare 1 stemi 1 säsongsinfluensavaccin för barn som nässpray 1 metreleptin 1 complete response letter (crl) 1 collaboration 1 avastin 1 depression 1 nsaid 1 xigduo 1 magnus björsne 1 mölndal 1 torrent pharma 1 american college of rheumatology 1 psoriasis 1 NSCLC 1 cytofab 1 kvadrivalent 1 UCR 1 Zavicefta 1 forskarkarriärer 1 amend 1 oic 1 rosuvastatinkalcium 1 amylin 1 äggstockscancer 1 registreringsansökan 1 budesonid 1 diagnostik 1 jupiter-studien 1 jupiter 1 rosuvastatin 1 hyperkolesterolemi 1 merck 1 viktökning 1 schizofreni 1 apollo 1 amylin pharmaceuticals 1 pa 1 norge 1 nya läkemedel 1 iressa 1 grymt fett en filmserie om tonårshjärnan 1 renaissance 5 1 gensekvensering 1 sjukhussjuka 1 remissvar prismodell 1 illumina 1 fluenz tetra 1 delårsrapport januari - mars 1 pascal soriot 1 innovation 1 halvårsresultat 1 ipass 1 mdr-tb 1 right honourable baroness shriti vadera 1 pet 1 renaissance 4 1 sjukhusinfektioner 1 säsongsinfluencavaccin 1 akuta koronara syndrom 1 södertälje 1 yngre forskare 1 strategiska centra 1 antibiotikum 1 produktionschef 1 världsdiabetesdagen 2014 1 saxagliptin 1 halvårsrapport 1 nktr-118 1 gikt 1 opioidorsakad 1 gener 1 patientundersökning 1 healthy heart africa 1 biokemiska markörer 1 ann cairns 1 sommarforskarskola 1 svenska lungcancerstudiegruppen 1 Visa alla taggar
Media no image
Media no image
Media no image

Fasenra receives approval in Japan

Pressmeddelanden   •   Jan 19, 2018 08:06 CET

Risk of repeat heart attack twice as likely from occlusions in arteries that did not cause initial event

Risk of repeat heart attack twice as likely from occlusions in arteries that did not cause initial event

Pressmeddelanden   •   Jan 16, 2018 16:42 CET

AstraZeneca announced today the publication of a new analysis from an ongoing real-world quality registry that suggests the risk of experiencing a repeat heart attack (also known as a myocardial infarction or MI) from occlusions in non-stentedarteries is twice as high as the risk stemming from the initially stented artery following a first heart attack.

Lynparza approved by US FDA in germline BRCA-mutated   metastatic breast cancer

Lynparza approved by US FDA in germline BRCA-mutated metastatic breast cancer

Pressmeddelanden   •   Jan 12, 2018 17:20 CET

AstraZeneca and Merck & Co., Inc., Kenilworth, N.J., US (Merck: known as MSD outside the US and Canada) today announced that the US Food and Drug Administration (FDA) has approved Lynparza (olaparib), for use in patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm),

Fasenra receives EU approval for severe  eosinophilic asthma

Fasenra receives EU approval for severe eosinophilic asthma

Pressmeddelanden   •   Jan 10, 2018 16:28 CET

AstraZeneca and its global biologics research and development arm, MedImmune, today announced that the European Commission (EC) has approved Fasenra (benralizumab) as an add-on maintenance treatment in adult patients with severe eosinophilic asthma inadequately controlled despite high-dose inhaled corticosteroids plus long-acting beta-agonists.

Media no image
Media no image

AstraZeneca to highlight its commitment to blood cancers at the 2017 American Society of Hematology Annual Meeting

Pressmeddelanden   •   Dec 06, 2017 08:02 CET

AstraZeneca, along with Acerta Pharma, its haematology research and development centre of excellence, and MedImmune, its global biologics research and development arm, will highlight significant progress in blood cancer research at the 59th 2017 American Society of Hematology (ASH) Annual Meeting & Exhibition in Atlanta, USA

Tudorza reduces exacerbations and demonstrates cardiovascular safety in COPD patients

Tudorza reduces exacerbations and demonstrates cardiovascular safety in COPD patients

Pressmeddelanden   •   Dec 04, 2017 08:04 CET

AstraZeneca today announced positive top-line results of the Phase IV ASCENT trial for Tudorza Pressair (aclidinium bromide 400 μg, twice-daily), a long-acting muscarinic antagonist (LAMA), in patients with moderate to very severe chronic obstructive pulmonary disease (COPD), with a history of cardiovascular disease and/or significant cardiovascular risk factors.

The European Medicines Agency accepts regulatory submission for Tagrisso in 1st-line EGFR-mutated non-small cell lung cancer

The European Medicines Agency accepts regulatory submission for Tagrisso in 1st-line EGFR-mutated non-small cell lung cancer

Pressmeddelanden   •   Nov 28, 2017 08:15 CET

AstraZeneca today announced that the European Medicines Agency has accepted a variation to the Marketing Authorisation Application (MAAv) for Tagrisso (osimertinib),

AstraZeneca and Chinese Future Industry Investment Fund establish joint venture to develop new medicines in China

AstraZeneca and Chinese Future Industry Investment Fund establish joint venture to develop new medicines in China

Pressmeddelanden   •   Nov 27, 2017 08:17 CET

AstraZeneca today announced a strategic joint venture with the Chinese Future Industry Investment Fund (FIIF) to form an equally-owned, stand-alone company in China to discover, develop and commercialise potential new medicines to help meet unmet needs globally, and to bring innovative new medicines to patients in China faster.

AstraZeneca makes regulatory submission for Tagrisso in 1st-line EGFR-mutated non-small cell lung cancer in Japan

AstraZeneca makes regulatory submission for Tagrisso in 1st-line EGFR-mutated non-small cell lung cancer in Japan

Pressmeddelanden   •   Nov 27, 2017 08:04 CET

AstraZeneca today announced the submission of a supplemental new drug application (sNDA) to Japan’s Pharmaceuticals and Medical Devices Agency for the use of Tagrisso (osimertinib).

Media no image
Fasenra (benralizumab) receives US FDA approval for severe eosinophilic asthma

Fasenra (benralizumab) receives US FDA approval for severe eosinophilic asthma

Pressmeddelanden   •   Nov 15, 2017 08:01 CET

AstraZeneca and its global biologics research and development arm, MedImmune, today announced that the US Food and Drug Administration (FDA) has approved Fasenra (benralizumab) for the add-on maintenance treatment of patients with severe asthma aged 12 years and older, and with an eosinophilic phenotype.

Benralizumab får positivt CHMP-utlåtande i EU  för behandling av svår, okontrollerad eosinofil astma
AstraZeneca PLC:s resultatrapport för första nio månader och tredje kvartalet 2017
AstraZeneca shares scientific updates from its extensive cardiovascular, renal and metabolic diseases (CVMD) portfolio at AHA 2017

AstraZeneca shares scientific updates from its extensive cardiovascular, renal and metabolic diseases (CVMD) portfolio at AHA 2017

Pressmeddelanden   •   Nov 08, 2017 08:02 CET

AstraZeneca and MedImmune, its global biologics research and development arm, will be underlining its scientific focus on cardiovascular, renal and metabolic diseases (CVMD) with 28 presentations, including two late-breaking trials, at the American Heart Association (AHA) Scientific Sessions, November 11-15, 2017 in Anaheim, California.

AstraZeneca provides update on tralokinumab Phase III Programme in severe, uncontrolled asthma
FDA godkänner AstraZenecas Calquence (acalabrutinib) för vuxna patienter med tidigare behandlad mantelcellslymfom

FDA godkänner AstraZenecas Calquence (acalabrutinib) för vuxna patienter med tidigare behandlad mantelcellslymfom

Pressmeddelanden   •   Okt 31, 2017 18:23 CET

AstraZeneca och dess FoU-center för hematologi, Acerta Pharma, meddelar idag att den amerikanska läkemedelsmyndigheten FDA har godkänt Calquence(acalabrutinib) inom ramen för så kallat ”påskyndat godkännande” Calquence är en tyrosinkinashämmare och indikationen gäller behandling av vuxna patienter med mantelcellslymfom (MCL) som har fått minst en tidigare behandling. 1

 AstraZeneca and Incyte enter clinical trial collaboration in early lung cancer

AstraZeneca and Incyte enter clinical trial collaboration in early lung cancer

Pressmeddelanden   •   Okt 31, 2017 08:14 CET

​AstraZeneca and MedImmune, its global biologics research and development arm, today announced the expansion of their clinical collaboration with Incyte Corporation.